References
- Maini R, St Clair WE, Breedveld F, Furst D, Kalden J, Weisman M, et al. for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932–9.
- Day R. Adverse reactions to TNF-α inhibitors in rheumatoid arthritis. Lancet 2002;359:540–1.
- Krumme B, Conca W, Balle C, Peter HH, Schollmeyer P. Salmonella arthritis in a patient with severe lupus nephritis and thalassaemia minor. Nephron 1995;7:465–7.
- Miller SI, Pegues DA. Salmonella (including Salmonella typhi). In: Mandell, editor. Principles and Practice of Infectious Disease, 5th edn. Churchill Livingstone Inc; 1995. p. 2345–63.
- Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003;21(Suppl 2):S2–34.
- Bresnihan B, Cunnane G. Infection complications associated with the use of biological agents. Rheum Dis Clin North Amer 2003;29:185–202.
- Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicaemia in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48: 1853–7.
- Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumour necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315–8.